(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6 sorted by
relevance

Admin17.09.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

8508
Admin25.09.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

3010
Admin15.07.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

7301
Admin29.07.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

64010
Admin22.08.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

Admin25.09.2021

(PDF) A combination of anti-PD-L1 mAb plus Lm-LLO-E6

9308
Admin08.10.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

85010
Admin28.09.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

501
Admin29.09.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

2506
Admin14.07.2021

(PDF) Combination of MEDI0680, an anti-PD-1 antibody, with

3909
Admin16.09.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

3907
Admin16.08.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

81010
Admin14.09.2021

(PDF) Mechanisms involved in IL-15 superagonist

7401
Admin03.09.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

9409
Admin12.07.2021

(PDF) Targeting CXCR4 potentiates anti-PD-1 efficacy

Admin13.09.2021

Metastatic lung tumor nodules induced by TL-1 and SiHa

9509
Admin20.07.2021

(PDF) Immune Checkpoint Inhibitors in the Treatment of

5705
Admin20.08.2021

(PDF) PD-1/PD-L1 pathway: an adaptive immune resistance

2400
Admin26.09.2021

(PDF) Combination Antiangiogenic and Immunotherapy for

5603
Admin13.08.2021

(PDF) Which is the optimal immunotherapy for advanced

1803
Admin13.07.2021

(PDF) Targeting CXCR4 potentiates anti-PD-1 efficacy

3607